AIMS: Antibiotics In Miscarriage Surgery

AIMS: Antibiotics In Miscarriage Surgery

MedSciNet has developed and helped launch the online database for AIMS, a multinational, randomised, double-blind placebo-controlled trial to study the effectiveness of antibiotic prophylaxis in reducing the risk of infection resulting from the surgical evacuation of the uterus for miscarriage management in low income countries.

Infection following miscarriage surgery is a problem affecting over 33 million pregnancies each year. A majority of women will have their miscarriage managed with surgery to empty the womb. Infection can occur following this surgery and this is a particular problem in low income countries. In some low income countries the rates of infection following miscarriage surgery are as high as 30%. These infections can result in death, serious illness or long-term health problems.

Currently international and national medical guidelines do not recommend antibiotics to be given routinely in miscarriage surgery, because there is no evidence to suggest this to be effective.

The AIMS trial intends to test the hypothesis that pre-surgery prophylactic antibiotics given just before the procedure of miscarriage surgery may reduce the risk of pelvic infection within 14 days of surgery. The study will be conducted on 3400 miscarriage patients in Malawi, Uganda, Tanzania, and Pakistan.

The AIMS trial is being managed and sponsored by the University of Birmingham, United Kingdom and funded by the Medical Research Council, the Wellcome Trust, and the Department for International Development, United Kingdom.

To learn more, please visit the AIMS trial website at